Tech Company Financing Transactions

Cylene Pharmaceuticals Funding Round

Cylene Pharmaceuticals, operating out of San Diego, secured $44 million from HBM Healthcare Investments, Lilly Ventures and BioVentures Investors.

Transaction Overview

Company Name
Cylene Pharmaceuticals
Announced On
1/24/2007
Transaction Type
Venture Equity
Amount
$44,000,000
Round
Series C
Investors

HBM Healthcare Investments (Lead Investor) (Erich Platzer)

Lilly Ventures (Lead Investor) (Edward Torres)

BioVentures Investors

Mitsui & Co. Venture Partners

Novartis BioVenture Fund (Reinhard Ambros)

RCT BioVentures

Sanderling Ventures

Proceeds Purpose
Proceeds from the financing will be used to fund human clinical trials for Phase II studies of CX-3543 in several different cancer indications and to advance two more products into development. CX-3543, Cylene's most advanced product for the treatment of multiple cancers, acts as a Ribosomal RNA Biogenesis Inhibitor (RBI) by targeting a Protein:DNA interaction that is amplified in cancer cells during Pol I transcription of the rRNA genes.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5820 Nancy Ridge Dr. 200
San Diego, CA 92121
USA
Phone
(858) 875-5100
Website
www.cylenepharma.com
Email Address
[email protected]
Overview
Cylene Pharmaceuticalsdiscovers, develops and commercializessmall molecule drugs that target nucleolus and kill cancer cells.
Profile
Cylene Pharmaceuticals LinkedIn Company Profile
Social Media
Cylene Pharmaceuticals Company Twitter Account
Company News
Cylene Pharmaceuticals News
Facebook
Cylene Pharmaceuticals on Facebook
YouTube
Cylene Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
William Rice
  William Rice LinkedIn Profile  William Rice Twitter Account  William Rice News  William Rice on Facebook
Co-Founder
Daniel Hoff
  Daniel Hoff LinkedIn Profile  Daniel Hoff Twitter Account  Daniel Hoff News  Daniel Hoff on Facebook
VP - Bus. Development
Sean O'Brien
  Sean O'Brien LinkedIn Profile  Sean O'Brien Twitter Account  Sean O'Brien News  Sean O'Brien on Facebook
VP - Regulatory Affairs
John Lim
  John Lim LinkedIn Profile  John Lim Twitter Account  John Lim News  John Lim on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/24/2007: Wikio venture capital transaction
Next: 1/24/2007: Prospex Medical venture capital transaction

 

Share this article

 

Where The Data Comes From

We record funding rounds that are announced publicly. VC transactions on this site are sourced from publicly available VC deal announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.